Our technology combines optimized semiconductor manufacturing technique with unique biomediator preparation to achieve the first reliable POC biosensing platform. Sensors developed according to this method possess reproducibility, accuracy,stability that meet POC. Our sensors are portable, require low sample volume, do not require sample processing,are extremely suitable for use in POC settings. They can also be integrated into IoT systems to aide in rapid decision making,can be mass produced. Overall, we are the first to achieve accessible, reliable detection at the POC.

DBPR807, a safehighly specific CXCR4-targeting antagonist, has completed the concept validation of treating acute myocardial infarction (AMI) through both ratmini-pig animal disease models induced by occluding the left anterior descending artery (LAD). When DBPR807 (5 mg/kg, SC) was given in the rat model, a significant heart-protective effect was observed with reducing cardiac infarctionfibrosis by 4341, respectively. In the mini-pig model, DBPR807 (3 mg/kg, IV) treatment was allowed to improve 3-month LVEF up to 52 falling in a standard range between 50~70.